Abstract
BACKGROUND: Altered fractionated radiotherapy (AFR) has been used for many years in the treatment of cancer. Although AFR therapy improves tumor control, it also increases acute radiation toxicities, which may make patients withdraw from treatment. Here, we report on the efficacy of AFR in the treatment of nasopharyngeal cancer (NPC). METHODS: From September 1993 to October 1994, 68 NPC patients received AFR in Chang Gung Memorial Hospital-Linkou. The efficacy of two types of AFR were studied: (a) Hyperfractionated radiotherapy (HFT) in which irradiation was given twice a day throughout the radiotherapy course with a total radiation dose of 81.6 Gy/68 fractions in 7 weeks; and (b) Concomitant boost radiotherapy (CBT) in which additional concommitant radiotherapy was administered only during the last 2 weeks of the radiotherapy course. The total radiation dose of CBT was 72.3 Gy/42 fractions in 6 weeks. Twenty-six patients received HFT and 42 received CBT. RESULTS: The percentage of grade 3 complications was 73% in CBT and 65% in HFT. The mean number of treatment days was 57.1 in HFT (median, 53; range 48-63) and 43.9 in CBT (median, 43; range 40-60). No patient withdrew from or prolonged the treatment because of acute radiation toxicities. CONCLUSION: Our results demonstrated that NPC patients can tolerate HFT and CBT radiotherapy with sufficient psychological support. Further randomized trials will be continued in our institution.
| Original language | English |
|---|---|
| Pages (from-to) | 107-114 |
| Number of pages | 8 |
| Journal | Chang Gung Medical Journal |
| Volume | 20 |
| Issue number | 2 |
| State | Published - 06 1997 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Acute toxicities and feasibility of altered fractionated radiotherapy in nasopharyngeal carcinoma.'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver